LA VILLE DE CHICAGO S'ASSOCIE À CHICAGO RIVER SWIM POUR RELANCER « THE BIG JUMP » ET PORTER LE NOMBRE DE PARTICIPANTS À 750 NAGEURS

L'événement « Chicago River Swim », organisé par la ville de Chicago et le maire Brandon Johnson, revient du 18 au 20 septembre. Des athlètes olympiques, paralympiques, internationaux et des personnalités locales, dont le maire de Dublin, se joindront aux habitants de Chicago pour célébrer la transformation de la rivière.

CHICAGO, 8 septembre 2026 /PRNewswire/ -- La traversée à la nage de la rivière Chicago, organisée par la ville de Chicago et le maire Brandon Johnson, réintroduira l'événement « The Big Jump » et élargira le nombre de participants pour l'édition 2026 à 750 nageurs qualifiés. Les inscriptions sont désormais ouvertes pour ces deux événements sur, ChicagoRiverSwim.org et.

Le « Big Jump » marquera le coup d'envoi du week-end, le vendredi 18 septembre, offrant aux participants inscrits une occasion unique et autorisée de se jeter à l'eau tout en collectant des fonds pour la recherche sur la SLA et l'apprentissage de la natation chez les jeunes. Le maire Johnson assurera le rôle de maître de cérémonie, aux côtés d'athlètes olympiques et paralympiques venus des États-Unis et d'ailleurs, notamment le médaillé d'or olympique néerlandais Maarten van der Weijden et le champion du monde tchèque de natation en eau glacée Max Munson, ainsi que des personnalités internationales du monde municipal, dont le maire de Dublin, Daryl Barron, et des personnalités éminentes de Chicago, parmi lesquelles la légende des Chicago Bears, Charles Tillman, et le producteur et DJ White Shadow, lauréat d'un Grammy Award.

« La rivière Chicago appartient à tous les habitants de Chicago, et The Big Jump est un moyen formidable de célébrer le chemin parcouru par notre ville », a déclaré le maire Brandon Johnson. « Depuis des générations, les habitants de Chicago s'efforcent de réhabiliter ce fleuve et de rétablir le lien entre nos communautés et celui-ci. En septembre prochain, des habitants de notre ville et du monde entier auront l'occasion de découvrir le fleuve sous un tout nouveau jour, tout en soutenant la recherche sur la SLA et en veillant à ce que davantage de jeunes aient accès à une formation en natation et en sécurité aquatique qui peut leur sauver la vie. »

« The Big Jump » fait revivre un événement organisé pour la première fois en 2017, lorsque Josina Morita, commissaire du comté de Cook, et l'association « Friends of the Chicago River » avaient réuni des élus à Chinatown pour un plongeon officiel dans la rivière. Cet événement a permis de célébrer les progrès réalisés dans la restauration de la rivière et a témoigné d'une volonté commune de faire en sorte que le réseau fluvial Chicago-Calumet soit sûr pour la baignade et accessible à tous.

La « Chicago River Swim », organisée par la ville de Chicago et le maire Brandon Johnson, est une épreuve de natation en eau libre à but caritatif qui se déroule le long du cours principal de la rivière Chicago. Lancée en 2025, cette première édition a réuni 263 nageurs dans la rivière à l'occasion de la première épreuve organisée de natation en eau libre à Chicago depuis 98 ans, attirant ainsi l'attention internationale sur ce cours d'eau désormais réaménagé.

« L'année dernière a prouvé que la natation pouvait faire son retour dans la rivière Chicago et prendre une dimension importante pour toute la ville », a déclaré Doug McConnell, fondateur de « A Long Swim » et de la « Chicago River Swim ». « Cette année, nous proposons davantage de façons de participer à cet événement, que ce soit en ouvrant "The Big Jump" au grand public ou en accueillant davantage de nageurs. Chaque participant nous aidera à collecter des fonds indispensables à la recherche sur la SLA et à proposer des cours de natation qui sauvent des vies à davantage d'enfants de Chicago. »

Cette année, la traversée à la nage de la rivière Chicago aura lieu le dimanche 20 septembre. La ville de Chicago a porté le nombre de participants admissibles de 500 à 750, rouvrant ainsi les inscriptions pour un nombre limité de participants aux épreuves d'un et de deux miles.

Ce week-end prolongé est le fruit de plusieurs décennies d'investissements, d'actions de sensibilisation, de recherches et de collaborations qui ont permis d'améliorer la qualité de l'eau et de faire de la rivière Chicago l'un des atouts récréatifs et civiques les plus importants de la ville. Ces progrès ont été rendus possibles grâce à la ville de Chicago, au Metropolitan Water Reclamation District of Greater Chicago, à l'association « Friends of the Chicago River », à Current, à l', au Shedd Aquarium, au Chicago Park District et à de nombreux autres partenaires publics, associatifs et communautaires. La qualité de l'eau fera l'objet d'une surveillance étroite avant et pendant tout le week-end, notamment grâce à des analyses réalisées par des experts en qualité de l'eau de l'Université de l'Illinois à Chicago.

PARTICIPATION INTERNATIONALE

Des athlètes olympiques et paralympiques, des nageurs de haut niveau et des personnalités locales de Chicago, de tous les États-Unis et du monde entier se réuniront à l'occasion du « Swim Weekend » ; parmi eux, des athlètes et des personnalités locales viendront notamment des Pays-Bas, du Mexique, de la République tchèque et d'Irlande. Leur participation témoigne d'un engagement commun en faveur de l'importance vitale de l'apprentissage de la natation, ainsi que d'une solidarité mondiale visant à protéger, à restaurer et à renouer les liens entre les populations et les rivières ainsi que les cours d'eau urbains.

La médaillée d'argent olympique américaine Maritza Correia McClendon participera aux deux épreuves au nom de la USA Swimming Foundation. Première femme afro-américaine à avoir intégré l'équipe olympique américaine de natation, elle mettra en avant le partenariat entre la Fondation et l'association Chicago River Swim, ainsi que leur engagement commun à élargir l'accès aux cours de natation qui sauvent des vies et à l'éducation à la sécurité aquatique.

« La traversée à la nage de la rivière Chicago est bien plus qu'une expérience inoubliable au cœur de l'un des cours d'eau les plus emblématiques de notre pays ; c'est l'occasion d'avoir un impact durable », a déclaré Correia McClendon. « Je suis fier de soutenir son partenariat avec la USA Swimming Foundation, qui permet à davantage d'enfants et de familles de Chicago d'acquérir des compétences de sauvetage qui leur serviront toute leur vie. »

Blake Pieroni, triple participant aux Jeux olympiques américains et médaillé d'or olympique, prendra le départ de l'épreuve de natation d'un mile dimanche. Originaire de Chesterton, dans l'Indiana, Pieroni a remporté la médaille d'or olympique au sein des équipes américaines du relais 4 × 100 mètres nage libre, tant en 2016 qu'en 2020.

Le médaillé d'or olympique néerlandais Maarten van der Weijden viendra des Pays-Bas pour représenter son pays et participera vendredi à l'événement « The Big Jump ». Ayant survécu à une leucémie et remporté une médaille d'or olympique en natation en eau libre, il a depuis organisé des épreuves de natation d'endurance exceptionnelles afin de collecter des millions pour la recherche contre le cancer. Le lien qui unit Chicago à la natation urbaine européenne va bien au-delà des participants de cette année. Doug McConnell, fondateur de Swim, s'est inspiré de la relation qu'entretient Amsterdam avec ses cours d'eau et du succès de l'Amsterdam City Swim, qui a démontré comment un cours d'eau urbain pouvait devenir la pièce maîtresse d'un événement communautaire d'envergure mondiale. McConnell attribue souvent cette inspiration à sa volonté de faire venir la nage en rivière à Chicago.

Le nageur olympique mexicain Jorge Andrés Iga César représentera le Mexique vendredi lors de l'événement « The Big Jump ». Iga César a participé aux Jeux de Paris 2024 et détient le record national mexicain du 200 mètres nage libre. Il a remporté quatre médailles aux Jeux panaméricains, dont une d'argent, ainsi que 19 médailles aux Jeux d'Amérique centrale et des Caraïbes.

Ahalya Lettenberger, double participante aux Jeux paralympiques américains et médaillée d'argent à Tokyo, participera à l'événement « The Big Jump » et prendra le départ de l'épreuve de natation d'un mile. Né à Chicago, Lettenberger a commencé la natation à l'âge de 11 ans et a ensuite représenté les États-Unis aux Jeux paralympiques de Tokyo et de Paris.

Grace Nuhfer, médaillée d'argent aux Jeux paralympiques, participera vendredi à l'événement « The Big Jump ». Originaire de l'Indiana, il a remporté la médaille d'argent aux Jeux de Paris 2024 au 100 mètres papillon S13, avant de devenir champion du monde dans cette épreuve en 2025. Elle a également remporté deux médailles de bronze aux Championnats du monde en natation libre.

Max Munson, l'actuel champion du monde de natation en eau glacée, participera vendredi à l'événement « The Big Jump » et prendra le départ de l'épreuve de natation d'un mile. Munson participera à cet événement depuis Prague, en République tchèque. Nageur accompli en piscine, en eau libre et en hiver, il est l'actuel champion du monde de natation sur glace dans sa catégorie d'âge aux épreuves de 50 mètres et 100 mètres nage libre, et a établi plusieurs records tchèques en nage libre.

Ce week-end accueillera également des personnalités internationales issues du monde associatif, notamment le maire de Dublin, Daryl Barron, qui se rendra à Chicago pour assister à la traversée à la nage de la rivière Chicago. Des élus, des personnalités, des responsables associatifs et d'autres invités d'honneur participeront également à l'événement ; d'autres noms seront annoncés ultérieurement.

« Dublin et Chicago entretiennent des liens historiques et culturels étroits, et je suis ravi d'être à Chicago pour assister à la traversée à la nage de la rivière Chicago », a déclaré Daryl Barron, maire de Dublin.

MOUNTAIN VIEW, Calif., Sept. 8, 2026 /PRNewswire/ -- Cyngn Inc. (Nasdaq: CYN), a leader in autonomous industrial vehicle technology, today shared an update from its CEO on the organizational, commercial, and product initiatives underway to sharpen the company's focus on enterprise customers and position Cyngn for its next phase of growth.

To our shareholders, customers, and partners,

I want to begin by thanking you for your continued support and confidence in Cyngn. Cyngn exists to help the world's largest industrial operations move materials autonomously, safely, and efficiently. As we've grown our enterprise pipeline and deepened our relationships with logistics, manufacturing, and warehousing customers, we have sharpened how we operate, doing more with the right team, the right tools, and a clearer product focus.

A Leaner Organization, Built to Harness Artificial Intelligence

We streamlined our organizational structure and reduced management layers, consolidating responsibilities and realigning resources around our highest-priority product, customer, and commercial initiatives. Flattening a layer of management and consolidating product and engineering teams shortens the distance between decision-making and execution and puts more of our resources directly against product and customer work. Combined with an expanded use of AI-assisted tools across engineering and business operations, from software development and simulation to sales operations and customer support, we believe this leaner structure lets us move faster with fewer handoffs, while improving our cost structure and extending our runway. We view this AI fluency a part of our DNA, not as a one-time efficiency gain but as a durable capability that will keep compounding as our teams get more comfortable with these tools.

Data Driven Sales Execution

We have also raised the bar on our commercial execution. We implemented changes to our sales leadership and processes, introduced data driven revenue operations, with a sharper focus on opportunity qualification, pipeline accountability, and the customers and applications best aligned with the capabilities and value proposition of our DriveMod Tugger. We believe this discipline will translate customer interest into scalable, repeatable deployments more consistently than before.

Strengthened Governance and Compliance

We've continued to strengthen our corporate governance, including our external audit and legal partnerships with Baker Tilly US, LLP, our independent registered public accounting firm, and Kaufman & Canoles, our corporate and securities legal counsel.

We expect to complete our SOC 2 and ISO 27001 certification efforts by the end of 2026, further supporting the financial reporting, security, and legal infrastructure behind our growth.

We're also watching the regulatory environment continue to shift in ways that favor the U.S.-based robotics and physical AI manufacturers, reinforcing our position as a domestic developer of autonomous industrial and Artificial Intelligence technology.

A leaner and more AI-enabled organization, a sharpened commercial process, and a focused enterprise product roadmap are all in service of the same goal: building Cyngn into the trusted autonomy partner for industrial customers at scale.

Thank you for being part of our journey. I look forward to keeping you updated as we execute against these goals.

Sincerely, Lior Tal Chairman and Chief Executive Officer, Cyngn Inc.

About Cyngn

Cyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges facing industrial organizations today, such as labor shortages and costly safety incidents.

Cyngn's DriveMod technology empowers customers to seamlessly bring self-driving technology to their operations without high upfront costs or infrastructure installations. DriveMod is currently available on Motrec MT-160 Tuggers.

The DriveMod Tugger hauls up to 12,000 lbs, travels inside and out, and targets a typical payback period of less than 2 years.

Investor Contact:

Natalie Russell

CFO

[email protected]

Media Contact:

Luke Renner

Head of Marketing

[email protected] 

Where to Find Cyngn:

- Website: https://cyngn.com

- X: https://x.com/cyngn

- LinkedIn: https://www.linkedin.com/company/cyngn

- YouTube: https://www.youtube.com/@cyngnhq

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission (SEC), including, without limitation the risk factors discussed in the Company's annual report on Form 10-K filed with the SEC on March 26, 2026. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Cyngn undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Cyngn

Share this article

ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Baird 2026 Global Healthcare Conference

Fireside Chat: Tuesday, September 15 at 8:30 a.m. ET

Location: New York, NY 

Morgan Stanley 24th Annual Global Healthcare Conference

Fireside Chat: Wednesday, September 16 at 8:30 a.m. ET

Location: New York, NY

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack

Corporate Communications

dcormack@regenxbio.com 

Investors:

George E. MacDougall

Investor Relations

IR@regenxbio.com

SOURCE REGENXBIO Inc.

Share this article

SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.

The complaint alleges that Unicycive failed to properly inspect its third-party vendor's manufacturing facility to ensure it resolved the U.S. Food and Drug Administration's ("FDA") previously noted deficiencies.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP before the November 2, 2026, lead plaintiff deadline.

Why Was Unicycive Sued?

According to the complaint, Unicycive submitted a New Drug Application ("NDA") for its kidney disease therapy, oxylanthanum carbonate ("OLC"), to the FDA in September 2024. The NDA was accepted by the FDA in November 2024. In June 2025, the FDA issued a Complete Response Letter ("CRL") citing deficiencies at a third-party manufacturing vendor. Following the CRL, Unicycive held a Type A meeting with the FDA in October 2025 to discuss the single deficiency related to the third-party manufacturing vendor's compliance status. After receiving official meeting minutes and engaging with the vendor, Unicycive resubmitted the NDA in December 2025.

Plaintiff alleges that, during the class period, defendants failed to disclose to investors:

(1) that the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices;

(2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies;

(3) that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices;

(4) that, as a result, the regulatory approval of OLC was reasonably likely to be delayed; and

(5) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did UNCY Stock Drop?

On June 30, 2026, before the market opened, Unicycive disclosed that the FDA had issued a CRL regarding the Company's resubmitted NDA for OLC, identifying the "same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025."

On this news, Unicycive's stock price fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, on unusually heavy trading volume.

Who May Be Eligible to Participate in the Unicycive Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. securities between December 29, 2025 and June 29, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Stockholders who wish to lead the class action should contact Robbins LLP before the November 2, 2026, lead plaintiff deadline.

Does it cost anything to participate?

No. Robbins LLP represents investors on a contingency fee basis.

Contact Robbins LLP

Investors seeking additional information about the Unicycive Therapeutics, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

About Robbins LLP

A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $1 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Unicycive Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

Share this article

Strong Unit-Level Economics and a Needs-Based, B2B Model Are Driving Reinvestment and Drawing Entrepreneurs Seeking Portfolio Diversification into the PuroClean System

Key takeaways:

- 20% of PuroClean's unit growth in 2026 has come from existing Franchise Owners reinvesting in additional territories

- A PuroClean Franchise Owner surpassed $20 million in gross sales from a single location for the first time in the brand's history*

- PuroClean's franchise development strategy is prioritizing entrepreneurs from the quick-service restaurant (QSR), hospitality, and retail spaces, among other multi-unit operators, as candidates for vertical integration into the brand

TAMARAC, Fla., Sept. 8, 2026 /PRNewswire/ -- PuroClean, the largest privately owned, commercial-focused restoration franchise with industry-leading unit-level economics, is continuing a strong year of growth with a run of franchise development milestones including a growing share of multi-unit ownership, and a franchise system that is attracting experienced entrepreneurs focused on portfolio growth.

"Growth like this doesn't happen by accident. It happens because we've built the operational infrastructure to support it," said PuroClean Steve White, President of PuroClean. "Whether it's a Franchise Owner adding additional territories or scaling towards record-setting sales, our job is to make sure the systems, training, and support behind them can grow just as fast as they do."

Multi-Unit Ownership Continues to Climb

Nearly half of all PuroClean Franchise Owners (44%) now operate multiple units, reinvesting in the brand as they scale. Just this year, 20% of PuroClean's unit growth has come from existing Franchise Owners adding territories, signaling strong confidence in the business model and the opportunity to scale within the PuroClean system.

A Track Record of Strong Unit-Level Performance

PuroClean entered 2026 on the heels of a record-setting performance, with a Franchise Owner surpassing $20 million in gross sales from a single location, a milestone that reinforces the strength of the brand's unit-level economics and the scalability of the PuroClean model. Results from the brand's onboarding and support programs are showing success across a broader group of Franchise Owners as they scale their businesses.

- New Franchise Owners reach their first job in an average of 45 days and those who enter the system without an employee make their first hire in an average of 27 days through the brand's PuroLaunch Program

- Franchise Owners with a dedicated sales representative average $1.4 million in revenue, with the top 10% average $5.9 million. **

"PuroClean has always been a needs-based business, and that is especially compelling for experienced operators looking to diversify their portfolios," said Brandon Mangual, Vice President of Franchise Development. "We already have successful Franchise Owners who came to PuroClean with experience operating brands like Dunkin', Subway, Hand & Stone, and Pizza Hut. We're building on that momentum by introducing more multi-unit business owners to restoration as a strategic vertical integration opportunity."

PuroClean is actively seeking enterprise builders, multi-unit operators, and franchisees from the QSR, retail, hospitality, home services, construction, HVAC, and plumbing sectors interested in adding a scalable, high-margin restoration business to their portfolio. More information on the franchise opportunity is available at purocleanfranchise.com.

*This figure represents the results of a single franchisee identified in Item 19 of our Franchise Disclosure Document ("FDD"). Individual financial performance will vary based on numerous factors. Prospective franchisees should carefully review the full FDD — including Item 19 — and consult with their own legal, financial, and business advisors before making any investment decision.

**With Sales Rep: See 2026 FDD

About PuroClean 

PuroClean is a leading, world-class service brand for water damage mitigation, fire and smoke damage restoration, mold remediation, and biohazard clean-up services, working with both residential customers and commercial clients across the U.S. and Canada. Founded in 2001, PuroClean is a diverse, fast-growing network of over 500 North American franchise locations, each independently owned and operated. With a commitment to respond within two hours, the professionals at PuroClean are thoroughly screened, insured, and trained in following the latest cutting-edge cleaning and restoration standards and practices. 

SOURCE PuroClean

Share this article

Auf dem richtigen Weg: Startchancen-Programm und Kita-SCQEG

Berlin (ots)

Heute hat die OECD die Ergebnisse der PISA-Studie 2025 vorgestellt. Die Ergebnisse zeigen dringenden Handlungsbedarf bei Bildungsqualität und Chancengerechtigkeit. Die SPD-Fraktion macht sich für beste Bildung und gleiche Chancen für jedes Kind stark.

Saskia Esken, Berichterstatterin für schulische Bildung:

"Die Ergebnisse der aktuellen PISA-Studie sind erneut ein Weckruf für die Bildungspolitik. Denn die Leistungsfähigkeit unseres Schulsystems lässt zu wünschen übrig. Natürlich entspricht es nicht unserem Anspruch, bei den Kompetenzwerten im internationalen Vergleich allenfalls Mittelmaß zu liefern und bei den Kernkompetenzen Lesen und Rechnen weiter abzustürzen. Doch obendrein hängt in kaum einem anderen Industrieland der Bildungserfolg der Kinder und Jugendlichen so stark von der sozialen Herkunft ab wie in Deutschland. Und es sind diese Kinder, die jetzt noch weiter abrutschen. Es schmerzt, dass die Bildungsgerechtigkeit weiter unser wunder Punkt ist. Unseren Schulen gelingt es nicht, die Nachteile auszugleichen, in die viele Kinder schon hineingeboren werden. In kaum einem anderen Land entscheidet die soziale Herkunft so stark über die Chancen und den Lebensweg der Menschen.

Wir haben in der vergangenen Legislatur mit dem Startchancenprogramm das größte Bildungsprogramm des Bundes auf den Weg gebracht. Trotz schwieriger Haushaltslage investieren wir zehn Jahre lang jedes Jahr eine Milliarde Euro Bundesmittel zusätzlich und ganz gezielt in die Förderung benachteiligter Schülerinnen und Schüler. Derzeit erreichen wir mit dem Programm etwa 10 Prozent der Schulen - mit einer erweiterten Finanzierung durch einen höheren Beitrag der sehr hohen Vermögen und Erbschaften in unserem Land könnte dieser Anteil gut auf 30 bis 50 Prozent gesteigert werden.

Bedeutsam ist ein besonderer Fokus auf den Kernkompetenzen des Lesens und Rechnens, die als Grundlage für eine erfolgreiche Bildung früh gefestigt werden müssen. Der Rechtsanspruch auf Ganztagsbetreuung in der Grundschule leistet nicht nur einen wichtigen Beitrag zur Vereinbarkeit von Familie und Beruf. Er schafft zudem Raum für die gezielte Förderung der Kinder auch am Nachmittag. Weil alle erkannt haben und längst wissen, dass es in der Bildung auf den Anfang ankommt, wird der richtige Ansatz des Startchancenprogramms nun auch in der Umsetzung des neuen Kita-Qualitätsentwicklungsgesetzes (Startchancen- und -Qualitätsentwicklungsgesetz - SCQEG) angewendet - damit die Unterstützung schon früh genau da ankommt, wo sie am dringendsten gebraucht wird. Bundesweite Qualitätsstandards für die Kinderbetreuung ebenso wie eine frühe Erhebung des Entwicklungsstands und bei Bedarf eine gezielte Sprach- und Entwicklungsförderung sind weitere wichtige Bausteine. Für die SPD ist aber auch klar: Bildung muss gebührenfrei sein - auch in der Kita! Wir wollen die frühkindliche Bildung in der Kita perspektivisch ohne Elternbeiträge finanzieren.

Die Ergebnisse der PISA-Studie zeigen, dass wir in dem Bemühen um bessere Bildung für alle Kinder nicht nachlassen dürfen und uns jederzeit um zusätzliche Mittel für eine Ausweitung der Programme bemühen müssen. Sehr hohe Einkommen und Vermögen müssen einen höheren Beitrag zum Gemeinwesen in Deutschland leisten und damit auch für mehr Bildungsgerechtigkeit. Alle Kinder haben beste Bildungschancen verdient."

Pressekontakt:

SPD-Bundestagsfraktion

- Die Pressestelle-

Telefon: 030 227 52728

E-Mail: presse@spdfraktion.de

Website: www.spdfraktion.de

Original-Content von: SPD-Bundestagsfraktion, übermittelt durch news aktuell

FOTON präsentiert neue Europa-Strategie auf der IAA Transportation 2026

Nutzfahrzeughersteller stellt in Hannover neue Elektro- und Wasserstofffahrzeuge vor

Bochum / Hannover / Unna (ots)

Der chinesische Nutzfahrzeughersteller FOTON nutzt die IAA Transportation 2026 in Hannover, um seine weitere Expansion in Europa vorzustellen. Im Mittelpunkt des Messeauftritts stehen die neue Europa-Strategie des Unternehmens, Fahrzeuge mit batterieelektrischen und wasserstoffbasierten Antrieben sowie der weitere Ausbau von Vertrieb, Service und Ersatzteilversorgung.

Die Nutzfahrzeugbranche befindet sich weltweit im Wandel. Elektrifizierung, Digitalisierung und die Reduzierung von CO2-Emissionen verändern sowohl Fahrzeuge als auch Transportkonzepte. Europa nimmt dabei aufgrund seiner hohen regulatorischen Anforderungen, der etablierten Transportwirtschaft und der unterschiedlichen Einsatzbereiche für Nutzfahrzeuge eine Schlüsselrolle ein.

FOTON verfolgt deshalb einen Ansatz, der über den reinen Export von Fahrzeugen hinausgeht. Neben der Einführung neuer Modelle baut das Unternehmen lokale Vertriebs- und Servicestrukturen auf und investiert in Fertigung, Lieferketten und Ersatzteilversorgung.

Europäischer Markt im Fokus

Mehrere batterieelektrische leichte Lkw und Transporter von FOTON verfügen bereits über die für den europäischen Markt relevanten Zulassungen und Zertifizierungen, darunter die EU-Gesamtfahrzeug-Typgenehmigung (WVTA). Auch Anforderungen im Zusammenhang mit VECTO, dem europäischen Verfahren zur Ermittlung von CO2-Emissionen und Kraftstoffverbrauch schwerer Nutzfahrzeuge, werden berücksichtigt.

Fahrzeuge der New-Energy-Marke CAVAN werden nach Unternehmensangaben derzeit in 15 europäischen Ländern sowie in weiteren internationalen Märkten wie Australien und Neuseeland eingeführt.

Parallel dazu baut FOTON seine internationale Produktions- und Lieferkettenstruktur aus. Weltweit verfügt das Unternehmen über 32 lokale Produktionsstandorte, unter anderem in Südostasien, Lateinamerika und dem Nahen Osten.

Gemeinsam mit COSCO Shipping Specialized Carriers hat FOTON zudem ein Joint Venture gegründet, das zusätzliche Transportkapazitäten für den Fahrzeugexport bereitstellen soll.

Ersatzteilzentrum in Unna stärkt europäischen After-Sales-Service

Ein wichtiger Baustein der europäischen Expansion ist das neue regionale Ersatzteilvertriebszentrum in Unna, Nordrhein-Westfalen. Das Zentrum hat inzwischen seinen Betrieb aufgenommen und soll eine schnellere Versorgung europäischer Kunden und Servicepartner mit Ersatzteilen ermöglichen.

Das RDC in Unna ergänzt das internationale After-Sales-Netzwerk von FOTON. Nach Angaben des Unternehmens umfasst dieses weltweit 18 Ersatzteilzentren, mehr als 1.200 Vertriebsstandorte und über 1.500 Servicepunkte. Ziel ist es, eine durchgängige und schnelle Ersatzteilversorgung sowie kürzere Reaktionszeiten im europäischen After-Sales-Geschäft zu gewährleisten.

Auch das internationale Geschäft des Herstellers wächst: Von Januar bis August 2026 exportierte FOTON nach eigenen Angaben rund 149.000 Fahrzeuge. Das entspricht einem Plus von 44,3 Prozent gegenüber dem Vorjahreszeitraum.

Weltpremiere des CAVAN BEACON in Hannover

Zu den Höhepunkten des Messeauftritts auf der IAA Transportation zählt die internationale Premiere des CAVAN BEACON. Der intelligente schwere Lkw ist als Plattform für unterschiedliche emissionsarme beziehungsweise lokal emissionsfreie Antriebskonzepte ausgelegt und soll sowohl mit batterieelektrischem Antrieb als auch mit Wasserstoff-Brennstoffzellentechnologie angeboten werden.

Insgesamt präsentiert FOTON in Hannover sieben Fahrzeuge mit neuen Antriebstechnologien sowie sechs selbst entwickelte Kernkomponenten. Die ausgestellten Lösungen richten sich an unterschiedliche Einsatzbereiche des europäischen Güter- und Wirtschaftsverkehrs.

Darüber hinaus nimmt FOTON die IAA Transportation zum Anlass, die weltweite Auslieferung seines 13-millionsten Fahrzeugs zu feiern. Gleichzeitig will das Unternehmen in Hannover weitere Details seiner künftigen Europa-Strategie bekannt geben.

Mit dem Ausbau von Produktportfolio, Vertrieb, Service, Ersatzteilversorgung und Lieferketten will FOTON seine Präsenz auf dem europäischen Nutzfahrzeugmarkt langfristig stärken.

Über FOTON

FOTON ist ein international tätiger Hersteller von Nutzfahrzeugen und bietet unter anderem leichte, mittelschwere und schwere Lkw, Transporter sowie Fahrzeuge mit alternativen Antriebstechnologien an. Das Unternehmen ist seit mehr als zwei Jahrzehnten auf internationalen Märkten aktiv und baut seine Aktivitäten in Europa derzeit weiter aus.

Pressekontakt:

Matthias Vogler

Marketing & Public Relations Manager

E-Mail: matthias.vogler@foton-motor.de

Original-Content von: BROCK Kehrtechnik GmbH, übermittelt durch news aktuell

In mehr als 700 Kinos: SAT.1 feiert mit ganz Deutschland DAS KINOFEST 2026

Unterföhring (ots)

Ein Fest für die ganze Familie: SAT.1 lädt als starker Partner ganz Deutschland zum KINOFEST am 12. und 13. September ein. An diesem Wochenende feiern Deutschlands Kino- und Verleihverbände - HDF KINO e.V., AllScreens e.V., AG Kino e.V. und AG Verleih e.V. - die Magie des Kinos und laden ganz Deutschland zum KINOFEST 2026 ein.

Bei diesem kulturellen Volksfest laufen in über 700 Kinos und auf über 2700 Leinwänden für 5EUR pro Ticket die neuesten Filmstarts: unter anderem "Steckerlfischfiasko" mit Sebastian Bezzel in der Hauptrolle, der neue Film von Star-Regisseur Paul Greengrass "The Uprising - Für die Freiheit", der Dokumentarfilm "Oasis: Don't Look Back In Anger" zur Reunion-Tour der britischen Erfolgsband "Oasis", "Bad Apples" mit der vielfach ausgezeichneten Schauspielerin Saoirse Ronan, der neue Teil der "Insidious"-Horrorfilmreihe "Insidious: Out of the Further", die Fortsetzung "Zauberhafte Schwestern 2" des Klassikers von 1998 mit Sandra Bullock und Nicole Kidman sowie die Romantik-Komödie "Finding Emily". Jeder Film, jeder Kinosaal, jeder Platz ist an diesem Wochenende Teil des KINOFEST 2026 und zum vergünstigten Preis zu erhalten. Darüber hinaus sind in den Kinos vor Ort wieder verschiedene Aktionen geplant.

Marc Rasmus, EVP Factual, Factual Entertainment, Fiction, Reality und SAT.1: "DAS KINOFEST 2026 feiert die Magie des Kinos. Ich freue mich sehr, dass SAT.1 dieses kulturelle Volksfest als starker Partner unterstützt. DAS KINOFEST war bereits im letzten Jahr mit über 1,65 Millionen Besuchern ein voller Erfolg und soll auch in diesem Jahr Kino für alle bezahlbar und zugänglicher machen und dabei die Film- und Kinokultur zu stärken. SAT.1 ist gerne Partner bei dieser wunderbaren Aktion."

Pressekontakt:

Stella Losacker

Content Communications

phone: +49 (0) 89 95 07 - 1168

email: stella.losacker@seven.one

Photo Production & Editing

Jessica Freko

phone: +49 175 1815489

email: jessica.freko@seven.one

SAT.1

Ein Unternehmen der Seven.One Entertainment Group

Original-Content von: SAT.1, übermittelt durch news aktuell

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

- This trial marks the fourth Phase I peptide study for Ascletis this year.

- ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT).

- ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in NHPs.

- ASC36 subcutaneous (SQ) injection demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide injection, respectively, in a head-to-head diet-induced obese (DIO) rat model.

- ASC36 oral tablets are expected to utilize a lower dose based on potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.

HONG KONG, Sept. 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it has initiated a U.S. Phase I study of ASC36 oral tablets (oral amylin receptor peptide agonist) for the treatment of obesity after recently receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).

The Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 following single and multiple ascending oral doses in 86 participants with obesity (body mass index (BMI) ≥ 30.0 kg/m²) or overweight (BMI ≥ 27.0 kg/m²).

"In 2026, we initiated four Phase I studies for our peptide pipeline, including ASC36 oral tablets, our fourth and most recent one, which represents a key milestone for Ascletis peptide pipeline and further validates our proprietary POTENT oral peptide delivery technology." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "ASC36 has demonstrated compelling preclinical weight-loss efficacy, favorable oral bioavailability and a prolonged half-life. We believe an effective oral amylin receptor agonist could offer a convenient, differentiated option for people with obesity. Combined with our oral small molecule and long-acting injectable programs, ASC36 further strengthens our diversified pipeline addressing the evolving treatment needs of patients with obesity and other metabolic diseases."

ASC36, an amylin receptor peptide agonist, was discovered and developed in-house utilizing Ascletis' proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD). ASC36 oral tablet formulation was developed and optimized by Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT) for delivery of oral peptides.

In non-human primates (NHPs), 10 mg ASC36 oral tablet per animal dosed once daily for seven days achieved absolute oral bioavailability[1] of 8% and elimination half-life of 116 hours at steady state; 25 mg ASC36 oral tablet per animal dosed once daily for seven days achieved absolute oral bioavailability of 6% and elimination half-life of 167 hours at steady state. The long elimination half-life (116 hours to 167 hours) of ASC36 oral tablets supports once-daily and less frequent oral dosing.

ASC36 oral tablets and subcutaneous (SQ) injection demonstrated significant weight loss in NHP and diet-induced obese (DIO) rat models, respectively. In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days. ASC36 tablets also reduced food intake significantly. In a head-to-head DIO rat model, after seven days of treatment, ASC36 SQ injection demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide injection, respectively.

Based on potentially better oral bioavailability and efficacy, ASC36 oral tablets are expected to utilize a lower dose, relative to a recently FDA approved oral GLP-1R peptide agonist. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected] 

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected]

SOURCE Ascletis Pharma Inc.

Share this article

Following a transition of ownership from Dr. Anthony Fasciano, the Bergen County office brings root canal therapy, surgical endodontics, and same-day emergency treatment to patients and referring dentists.

ENGLEWOOD CLIFFS, N.J., Sept. 8, 2026 /PRNewswire/ -- Modern Micro Endodontics has opened its ninth New Jersey office at 617 E. Palisades Ave, Suite 3 in Englewood Cliffs, following a transition of ownership from longtime Englewood Cliffs endodontist Dr. Anthony Fasciano, DMD. The office extends the practice's specialty endodontic care into Bergen County and adds appointment availability for area patients and referring dentists, including same-day treatment for dental emergencies.

Dr. Fasciano led the Englewood Cliffs practice for many years and selected Modern Micro Endodontics as his successor, announcing the transition in a letter to the dental community. He will remain with the office for a period of time to support the handoff, and longtime staff members will continue in their roles. The practice will operate at the same address, open Monday through Thursday from 9 a.m. to 5 p.m. and Friday from 9 a.m. to 3 p.m.

Modern Micro Endodontics has provided root canal therapy and other specialty endodontic treatment across Northern and Central New Jersey for more than a decade. The practice was founded by and is led by Dr. Vivian Graham, DDS, who earned her Doctorate of Dental Surgery from the Baltimore College of Dental Surgery and completed her endodontic residency at the University of Medicine and Dentistry of New Jersey. Dr. Graham has been recognized as a New Jersey Monthly Top Dentist for 14 consecutive years and is a member of the American Dental Association, the American Association of Endodontists, and the New Jersey Association of Endodontists.

Dr. Graham will be joined in Englewood Cliffs by Dr. Tara Mahpour, DMD, who received her Doctorate in Dental Medicine from Rutgers School of Dental Medicine and completed a General Practice Residency at Mount Sinai Hospital in New York City, followed by a post-doctoral endodontics residency at Rutgers. Her clinical research examined healing rates and prognostic factors following apicoectomy. Dr. Mahpour was named a 2026 New Jersey Monthly Top Dentist alongside Dr. Graham.

Because the practice is dedicated exclusively to endodontics, each office is equipped for detailed diagnosis and precise treatment, including surgical operating microscopes used in every procedure, cone-beam computed tomography, and EdgePRO laser technology. Referring dentists remain central to how the practice operates, and the Englewood Cliffs office is intended to shorten the time between referral and appointment for patients in Bergen County and surrounding towns.

"Opening our ninth location is about more than growth. It is about expanding access to exceptional endodontic care while maintaining the personalized experience that has always defined Modern Micro Endodontics," says Dr. Vivian Graham, DDS, founder and lead doctor at Modern Micro Endodontics. "Our focus remains unchanged: delivering exceptional endodontic care, investing in advanced technology and building lasting partnerships with the dentists who entrust us with their patients. We are grateful to Dr. Fasciano for his confidence, and we look forward to continuing the standard of care that patients and referring doctors in Englewood Cliffs have come to expect."

Modern Micro Endodontics provides a comprehensive range of endodontic services at all nine locations, including:

- Non-Surgical Endodontics

- Root Canal Therapy

- Surgical Endodontics

- Treatment for Cracked Teeth

- Traumatic Dental Injuries

- Facial Esthetics

- Emergency Treatment

About Modern Micro Endodontics

Modern Micro Endodontics is a specialty endodontic practice serving patients throughout Northern and Central New Jersey, combining advanced imaging and microscopic technology with a comfort focused approach to care. Prospective patients can learn more about Modern Micro Endodontics by visiting https://www.jcendo.com or by contacting one of the following locations:

- Englewood Cliffs: 617 E. Palisades Ave, Suite 3, Englewood Cliffs, NJ 07632, 201-894-0350

- Florham Park: 256 Columbia Turnpike, Suite 205 South Tower, Florham Park, NJ 07932, 973-765-0011

- Jersey City: 255 Newark Ave, Jersey City, NJ 07302, 201-369-9080

- Hoboken: 901 Washington Street, Hoboken, NJ 07030, 201-386-9080

- Millburn: 187 Millburn Ave, Suite 7, Millburn, NJ 07041, 973-258-9535

- Cedar Grove: 900 Pompton Ave, Ste B1, Cedar Grove, NJ 07009, 973-655-9080

- North Plainfield: 339 Somerset St, North Plainfield, NJ 07060, 908-650-7200

- Parsippany: 245 Baldwin Rd, STE 207, Parsippany, NJ 07054, 973-335-3700

- Bayonne: 356 Broadway, Bayonne, NJ 07002, 201-854-1356

SOURCE Modern Micro Endodontics

Share this article